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Structural basis of the activation of the CC chemokine 
receptor 5 by a chemokine agonist
Polina Isaikina1, Ching-Ju Tsai2, Nikolaus Dietz1, Filip Pamula2,3, Anne Grahl1, Kenneth N. Goldie4, 
Ramon Guixà-González2, Camila Branco5, Marianne Paolini-Bertrand5, Nicolas Calo5, Fabrice Cerini5, 
Gebhard F. X. Schertler2,3*, Oliver Hartley5,6*, Henning Stahlberg4†, Timm Maier1,  
Xavier Deupi2*, Stephan Grzesiek1*
The human CC chemokine receptor 5 (CCR5) is a G protein–coupled receptor (GPCR) that plays a major role in 
inflammation and is involved in cancer, HIV, and COVID-19. Despite its importance as a drug target, the molecular 
activation mechanism of CCR5, i.e., how chemokine agonists transduce the activation signal through the receptor, 
is yet unknown. Here, we report the cryo-EM structure of wild-type CCR5 in an active conformation bound to the 
chemokine super-agonist [6P4]CCL5 and the heterotrimeric Gi protein. The structure provides the rationale for 
the sequence-activity relation of agonist and antagonist chemokines. The N terminus of agonist chemokines 
pushes onto specific structural motifs at the bottom of the orthosteric pocket that activate the canonical GPCR 
microswitch network. This activation mechanism differs substantially from other CC chemokine receptors that 
bind chemokines with shorter N termini in a shallow binding mode involving unique sequence signatures and a 
specialized activation mechanism.
INTRODUCTION
The human CC chemokine receptor 5 (CCR5) is a G protein–coupled 
receptor (GPCR) that plays a major role in inflammation by recruit-
ing and activating leukocytes (1). CCR5 is also the principal HIV 
coreceptor (2), is involved in the pathology of both cancer (3) and 
neuroinflammation (4), and has been implicated in the inflammatory 
complications of coronavirus disease 2019 (COVID-19) (5, 6). Soon 
after the discovery of CCR5, it became evident that its natural chemo-
kine ligands inhibit HIV entry (7), with CCL5 (RANTES) being most 
efficient, acting both by blocking the binding site for the viral glyco-
protein gp120 and by promoting CCR5 endocytosis (8). Modifications 
of the N-terminal region of CCL5 preceding residue C10 yielded HIV 
entry inhibitors with significantly higher potency (9–11). These 
analogs belong to a group of over 100 engineered CCL5 N-terminal 
variants that show notable differences in their anti-HIV, endocytotic, 
affinity, and signaling properties ranging, e.g., from super-agonist 
to strong antagonist behavior (10, 11). The molecular basis of these 
N-terminal structure–related activity differences is currently unclear.
Whereas a good structural understanding has been reached of 
the activation mechanisms of class A GPCRs by small-molecule li-
gands (12), the activation mechanism of the chemokine receptor 
subclass is not yet well understood. Inactive structures of a number 
of chemokine receptors have been solved, including complexes of 
CCR5 with the engineered chemokine antagonist [5P7]CCL5 (13), 
the viral gp120•human CD4 complex (14), the HIV inhibitor mara-
viroc (15), and other small-molecule antagonists (16). In contrast, 
only two active-state human chemokine receptor complex structures 
are currently available: CCL20•CCR6•Go (17) and CXCL8•CXCR2•Gi 
(18). In these structures, CCL20 and CXCL8 adopt a shallow binding 
mode in which the chemokine N terminus is not deeply inserted 
into the orthosteric pocket and activation apparently involves trans-
mission of forces directly from the extracellular domain of the receptor. 
There are also two inverse-agonist–bound (19), one agonist-bound, 
and one apo (20) structures available of the viral chemokine recep-
tor US28. All these structures are in active conformation. However, 
US28 is constitutively active and can engage thousands of distinct 
chemokine sequences, some of them leading to a moderate increase 
in activity (20). Thus, chemokine-induced activation of US28 is thought 
to result from a rather sequence-insensitive mechanism, in which 
the steric bulk of the ligand is more important than specific interac-
tions between the chemokine and the receptor (20).
In contrast to CCR6 and CXCR2, many native human chemo-
kine receptors such as CCR5 have chemokine ligands with longer N 
termini, which likely insert more deeply into the orthosteric pocket 
of the receptor. As many agonist and antagonist CCL5 ligand variants 
have been identified for CCR5 that differ only in the composition 
of the first ~10 residues but not in their length (11). The decisive 
contacts for CCR5 signaling interactions must be located at the 
bottom of the orthosteric pocket rather than at the extracellular 
surface of the receptor.
With the aim of elucidating the apparently different activation 
mechanisms of CC chemokine receptors and to provide a general 
structural explanation for the variable pharmacology of CCL5 
N-terminal variants, we solved the structure of wild-type human 
CCR5  in complex with the super-agonist [6P4]CCL5 and the Gi 
heterotrimer.
RESULTS
Overall structure of the [6P4]CCL5•CCR5•Gi complex
A stable [6P4]CCL5•CCR5•Gi complex was obtained by incubating 
detergent-solubilized human wild-type full-length CCR5 with the 
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Gi heterotrimer and [6P4]CCL5 (fig. S1). The complex was treated 
with apyrase to hydrolyze guanosine diphosphate and was further 
stabilized by addition of the Fab fragment Fab16 (21, 22), which 
recognizes an interface between the G and G subunits of the Gi 
heterotrimer (fig. S2). Single-particle cryo–electron microscopy 
(cryo-EM) analysis with extensive particle classification yielded a 
three-dimensional (3D) density map with a nominal global resolu-
tion of 3.15 Å (Fig. 1A, fig. S3, and table S1). The map is well re-
solved for most of parts of CCR5, the [6P4]CCL5 N terminus, the Gi 
heterotrimer (fig. S4), and Fab16. The density of the globular core 
of [6P4]CCL5 and the adjacent CCR5 N terminus and extracellular 
parts of the receptor have less defined density, indicating relative 
flexibility in these parts of the structure. A 3D variability analysis of 
the cryo-EM data (movie S1) and molecular dynamics (MD) simu-
lations of the atomic model (fig. S5A) reveal a certain degree of 
mobility of the [6P4]CCL5 core, the receptor N terminus, the extra- 
and intracellular loops, and transmembrane (TM) helices 5, 6, 
and 7. Still, the MD simulations indicate persistent interactions 
mediated by the N-terminal residues 0 to 8, the 1/3-strands, and 
the 30s loop of the chemokine (fig. S5B). Apart from a small ~5° 
difference in the orientation, the position of the [6P4]CCL5 core is 
very similar to that of [5P7]CCL5 in the inactive [5P7]CCL5•CCR5 
complex (Figs. 1C and 2A). Nevertheless, this minor change in ori-
entation also leads to small (1 to 2 Å) but noticeable movements at 
the extracellular ends of TM1 and TM7 (Fig. 2B).
The open conformation of the intracellular part of the active 
CCR5 differs from all inactive CCR5 structures, thereby enabling 
binding of the G protein (Fig. 1C): TM6 is moved outward from the 
heptahelical bundle accompanied by further rearrangements of TM5, 
TM7, and intracellular loop 4 (ICL4). The moderate outward movement 
of TM6 and the arrangement of Gi relative to CCR5 (Fig. 1, A to C) 
agree with previous GPCR•Gi complexes (23).
CRS1 interactions
The interactions between [6P4]CCL5 and CCR5 can be separated into 
the three canonical chemokine recognition sites (CRS): CRS 1, 1.5, 
and 2 (Fig. 2C) (13, 24). CRS1 consists of the contacts of the chemo-
kine core with the extracellular side of the receptor and is dominated 
by electrostatic interactions. The core of [6P4]CCL5 sits on top of a 







































Fig. 1. Cryo-EM structure of the [6P4]CCL5•CCR5•Fab16 complex. (A) Cryo-EM map of the [6P4]CCL5•CCR5•Gi•Fab16 complex colored by subunits ([6P4]CCL5, 
magenta; CCR5, green; Gi, blue; G, orange; G, maroon; and Fab16, gray). (B) Atomic model of the [6P4]CCL5•CCR5•Gi•Fab16 complex in the same view and color 
scheme as shown in (A). (C) Side and cytoplasmic views of the structural overlay of active CCR5 (green) in complex [6P4]CCL5 (magenta) and inactive CCR5 [orange; 
Protein Data Bank (PDB) ID: 5UIW] in complex with [5P7]CCL5 (yellow). Substantial structural changes between two conformations are indicated by red arrows. The 
C1013.25-C178ECL2, C20N-term-C2697.25 disulfide bridges conserved in chemokine receptors are shown in dark yellow. (D) Interactions between the [6P4]CCL5 core and 
the CCR5 N terminus at the CRS1 site (left, cryo-EM structure; right, cryo-EM/NMR–based model). In the model, sulfo-tyrosines sY10 and sY14 are depicted as sticks, and 









Isaikina et al., Sci. Adv. 2021; 7 : eabg8685     16 June 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
3 of 12
which is shaped by two disulfide bridges [C1013.25-C178ECL2, con-
served in class A GPCRs, and C20N-term-C2697.25, specific to chemo-
kine receptors; superscripts indicate the GPCRdb numbering scheme 
(25)] (Figs. 1C and 2A). The [6P4]CCL5 strand 1 makes extensive 
contacts with polar residues in extracellular loop (ECL) 2, while the 
CCR5 N terminus directs toward a shallow groove between the 
chemokine N-loop and 40s loop forming further extensive ionic and 
polar interactions. Interactions between CCR5 residues S17 and E18 
and the chemokine residues R47 and Q48 are visible in the density. 
However, poorly defined density prevented building a model of the 
CCR5 N-terminal residues 1 to 15 with confidence. To gain insights 
into this region, these CCR5 residues were modeled (Fig. 1D) on the 
basis of the nuclear magnetic resonance (NMR) structure of CCL5 
in complex with an N-terminal fragment (residues 1 to 27) of CCR5 
sulfated at residues Y10 and Y14 (26). Sulfation at Y10 and Y14 of 
CCR5 is important for chemokine affinity (26–29) and is expected to 
be present also in the insect cell–expressed CCR5 used in the cur-
rent study (30). The stability of the modeled interactions between 
the sulfated CCR5 N terminus and [6P4]CCL5 was assessed by MD 
(movie S2). The simulations reveal persistent interactions between 
sY10 and sY14 of CCR5 and residues in the N-loop, 40s loop, and 
3-strand (fig. S6), including K45, R47, and R17 of [6P4]CCL5, in 
complete agreement with the NMR-observed nuclear Overhauser effect 
(NOE) contacts (29). In addition, comparison of MD trajectories 
between sulfated and nonsulfated CCR5 indicates that sulfation in-
duces a higher number of contacts between the chemokine and the 
receptor N terminus (fig. S6), consistent with the higher affinity of 
the sulfated form (28).
CRS2 interactions and activation
The N terminus of [6P4]CCL5 reaches deep into the orthosteric 
pocket (CRS2) between the CCR5 7TM bundle (Fig. 2). In complete 
agreement with this deep binding mode, point mutations of many 
CCR5 residues lining the CRS2 site, the CRS1.5 site at the rim of the 
orthosteric pocket, and the extracellular N-terminal CRS1 site have 
been shown previously to affect the affinity of CCR5 for chemo-
kines (Fig. 2D). This deep insertion contrasts with the shallow bind-
ing modes observed for the chemokines in the CCL20•CCR6•Go 
(17) and CXCL8•CXCR2•Gi (18) complexes (see below). Of note, 
the N-terminal residues preceding C10 and C11 of monomeric 
CCL5 in solution undergo large amplitude motions on the nanosecond 
time scale, as revealed by 15N relaxation data (31). However, they 
adopt a fixed conformation in the CCR5 complex.
The [6P4]CCL5 residues 0 to 3 form the distal N terminus, which 
is located at the bottom of CRS2 (Figs. 2, A and C, and 3, A and B). 
As compared to [5P7]CCL5, the deeper binding pose of [6P4]CCL5 
slightly relocates the N-terminal pyroglutamate (PCA) group 
(Fig. 3A). The packing of CCR5 against the PCA group is not very 


























































Fig. 2. Deep insertion of CCL5 chemokines into the orthosteric CCR5 ligand pocket. (A and B) Comparison between the insertion of the agonist [6P4]CCL5 (magenta) 
into active CCR5 (green) and the antagonist [5P7]CCL5 (yellow) into inactive CCR5 (orange; PDB ID: 5UIW) (A, side view; B, top view). Only the CCL5 N-terminal residues 
are shown in (B). Important residues participating in the CCL5-CCR5 interaction are marked. (C) Location of CRS1, CRS1.5, and CRS2 chemokine recognition sites in the 
[6P4]CCL5•CCR5•Gi complex. (D) Locations of previously identified CCR5 point mutants [as reviewed by (13)] that affect chemokine affinity within CCR5. Respective resi-
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tight, and our MD simulations of the [6P4]CCL5•CCR5 complex 
show that the PCA group interacts through dynamic water-mediated 
hydrogen bonds with nearby residues Q1945.38 and Y2516.51 (fig. S7A). 
An inspection of the electron density of the [5P7]CCL5•CCR5 crystal 
structure (13) allowed us to also model additional water molecules 
in the vicinity of the [5P7]CCL5-PCA, which similarly connect to 
surrounding residues K1915.35, Q1945.38, Y2516.51, N2586.58, and 
T2596.59 (fig. S7B). Thus, the PCA group of the chemokine does not 
appear to have well-defined contacts to CCR5. Rather, the surround-
ing CCR5 cavity may accommodate even larger moieties such as the 
alkyl chains of AOP- (9) or PSC-CCL5 (32), thereby increasing the 
potency of these ligands.
[6P4]CCL5 residues 4 to 9 form the proximal N terminus, which 
acts as a hinge between the chemokine core and the distal N termi-
nus (Figs. 2, A and C, and 3, A and B). Conspicuously, residues P3 
to D5, which constitute the turn between the proximal and the dis-
tal [6P4]CCL5 N terminus, insert several angstroms deeper into the 
CCR5 orthosteric pocket than the corresponding residues of [5P7]
CCL5 or the V3 loop of gp120 in the respective inactive complexes 
with CCR5 (Fig. 3A). Because of this deeper insertion, P3 of [6P4]
CCL5 can displace CCR5 M2877.43 and Y1083.32 (Fig. 3, A and B), 
thereby apparently activating the canonical GPCR microswitch net-
work (see below), which remains in the inactive conformation in 
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Fig. 3. Activation mechanism of CCR5 by [6P4]CCL5 at CRS2. (A) Comparison of insertion depths of agonist [6P4]CCL5 (magenta), antagonist [5P7]CCL5 (yellow), and 
the antagonist V3 loop of gp120 (slate; PDB ID: 6MEO) into active CCR5 (green) and inactive CCR5 (orange). Important interacting residues are shown as sticks. (B) Detailed 
view of [6P4]CCL5 N terminus inserted into active CCR5, [5P7]CCL5 N terminus, and gp120 V3 loop inserted into inactive CCR5; and comparison of the insertion of [6P4]
CCL5 N terminus into active CCR5 and of CCL20 N terminus into active CCR6 (PDB ID: 6WWZ). (C) Sequence composition of the N termini of CCL5 natural amino acid 
variants (table S2) with low (≤20%, N = 83, top) and high (≥50%, N = 34, bottom) calcium signaling. The N termini of [5P7]CCL5, [6P4]CCL5, and wild-type CCL3 to CCL5 (all 
agonists) are shown below. (D) Effect of CCR5 (left) and CCL5 (right) mutations on CCR5 signaling activity as monitored by Ca2+ flux measurements in human embryonic 
kidney (HEK) cells. Data points represent mean peak height ± SD (n = 3). Data shown are representative of two (left) or three (right) independent experiments. Fits to data 
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mechanism involving M2877.43 has been suggested on the basis of a 
computational model of the CCR5/CCL5 complex (13).
The deeper pose of the [6P4]CCL5 N terminus partially overlaps 
with that of the antagonist maraviroc (fig. S8) (15). However, mar-
aviroc inserts its phenyl ring between Y1083.32 and F1093.33 of the 
“aromatic connector” (see below), thereby apparently blocking the 
conformational rearrangement necessary for activation. A compar-
ison of the chemokine N termini in the [6P4]CCL5•CCR5 versus 
the CCL20•CCR6 complexes (Fig. 3B) also shows the much reduced 
insertion depth of the latter, which prevents it from reaching sites 
corresponding to the activation switches identified at the bottom of 
the orthosteric pocket of CCR5.
The different insertion depth of the [6P4]CCL5 and [5P7]CCL5 N 
termini into CRS2 is caused by a markedly different structure of 
their proximal N-terminal residues 5 to 8, a short helix in [5P7]
CCL5 and an extended coil in [6P4]CCL5 (Fig. 2, A and B, and 
3, A and B). The hinge function of this structure is presumably key 
to the control of receptor activation. In [6P4]CCL5, D5 of the ex-
tended hinge forms an ionic interaction with K261.28 in TM1, 
whereas the side chain of the equivalent M5 of [5P7]CCL5 points in 
the opposite direction forming a helical turn (Fig. 3B). Apparently, 
this helical turn is also pushed sideways by unfavorable interactions 
between [5P7]CCL5 L7 and K261.28. Very similar interactions and 
conformations are present in the inactive gp120•CCR5 complex, 
with F315, R313, and P311 taking the roles of [5P7]CCL5 L7, M5, 
and P3, respectively. Besides the ionic D5-K261.28 interactions, the 
extended backbone at residues 2, 4, and 5 of the active [6P4]CCL5 is 
further stabilized by contacts to E2837.39.
The structural finding that the CCL5 the N-terminal hinge con-
formation controls the insertion depth of its residues 3 to 5 and 
thereby the activation state of CCR5 is corroborated by a statistical 
analysis of the pharmacological properties of CCL5 N-terminal 
amino acid variants. Currently, ~140 of these have been character-
ized for G protein signaling (table S2), CCR5 internalization, and 
anti-HIV activity (11). Sequence analysis shows that residues 0 to 3 
(highest abundance: QGPL, distal N terminus) and 8 and 9 (highest 
abundance: QV, proximal N terminus) are highly similar between 
N-terminal variants with low (N = 83) and high (N = 34) signaling 
activity (Fig. 3C). The latter is expected since the panel of tested 
variants was to some extent biased toward these residues (11). In 
contrast, strong differences are observed for residues 4 to 7 in the 
proximal N terminus: In agonist variants, the small, hydrophilic, or 
negatively charged amino acids S, Q, G, and D dominate, whereas 
antagonist variants contain mostly the large hydrophobic amino ac-
ids L, M, and W. Apparently, the small hydrophilic residues direct 
the hinge toward K261.28 in TM1, whereas the large hydrophobic 
residues make the hinge collapse to a helical turn. In agreement 
with their agonist pharmacology, both [6P4]CCL5 and wild-type 
CCL5 as well as the other major CCR5 agonist chemokines CCL3 
(MIP1) and CCL4 (MIP1) contain an aspartic acid residue at po-
sitions 5 or 6 (Fig. 3C), which presumably stabilizes the extended 
hinge by forming a salt bridge to K261.28.
Essential parts of the proposed CCR5 activation mechanism 
were tested by CCR5 and [6P4]CCL5 point mutants using cellular 
Ca2+ flux activation assays in human embryonic kidney (HEK) cells 
(Fig. 3D and table S3). Consistent with our model, the CCR5 
M2877.43A, Y1083.32A, and E2837.39A mutations all reduced Emax for 
[6P4]CCL5 activation by ~40 to 70% without affecting the half-maximal 
effective concentration (EC50). This indicates that these mutations 
reduce signaling without modifying chemokine affinity. In contrast, 
the [6P4]CCL5 D5A and D5K mutations decreased Emax by 30 and 
60%, respectively and increased EC50 ~5- to 10-fold. Similar obser-
vations were made in Chinese hamster ovary (CHO) cells express-
ing CCR5 (table S3). The fact that these [6P4]CCL5 mutations 
reduce both signaling and binding affinity agrees with our proposed 
mechanism, since the unfavorable interactions of the CCR5 residue 
K261.28 with an alanine or lysine at position 5 in [6P4]CCL5 are ex-
pected to alter the hinge structure and reduce the binding enthalpy.
Signal transmission from CRS2 to the microswitch network
As described above, the straight conformation of the [6P4]CCL5 
proximal N terminus pushes the region around residue P3 toward 
the bottom of CRS2, with the backbone of residues 2, 4, and 5 of 
[6P4]CCL5 interacting with E2837.39 (Fig. 4A). The straight hinge 
appears to be further stabilized by contacts of [6P4]CCL5 residues 
P3 to D5 to a cluster of the hydrophobic CCR5 residues F852.59, 
W862.60, Y892.63, and L1043.28. These contacts may act as “counter 
bearing” to promote the force of the [6P4]CCL5 N terminus toward 
the bottom of CRS2.
The deeper placement of residue P3 of [6P4]CCL5 as compared 
to [5P7]CCL5 forces a relocation of M2877.43 in the receptor (Figs. 3A 
and 4A), which is accompanied by noticeable local changes in the 
backbone of TM7 (fig. S9) that bring the intracellular half of this 
helix toward the receptor core. This movement allows H2897.45 to 
push onto W2486.48, possibly assisting the relocation of TM6 (Fig. 4A). 
P3 also lies on top of an aromatic connector formed by CCR5 resi-
dues Y1083.32, F1093.33, and F1123.36 (Fig.  4B), forcing the move-
ment of Y1083.32 and resulting in a cascade of aromatic side chain 
relocations that transmit the activation signal to the receptor core. 
This apparently switches the PIF motif (P2065.50, I1163.40, and 
Y2446.44) to an active conformation (Fig. 4D) and induces the large-
scale movement of TM6. The relocation of TM6 and TM7 coincides 
with local structural changes in the NPxxY motif (Fig. 4C), leading 
to the formation of the conserved water- mediated interaction be-
tween Y2977.53 and Y2145.58 (33) and the opening of the binding 
pocket for H5 of Gi, which includes R1263.50 in the open conforma-
tion of the intrahelical ionic lock of the DRY motif (Fig. 4E). The 
MD simulations show that all these mentioned residues maintain 
stable contacts corresponding to the active conformation of the 
receptor (fig. S10).
An overview of all CCR5 point mutations (either previously de-
scribed or generated in this study) that hinder signaling but do not 
reduce chemokine binding (Fig. 4F) confirms the essential aspects 
of the global signal transmission from the chemokine binding site 
to the canonical GPCR microswitch network. Such mutations com-
prise (i) F852.59, Y892.63, and L1043.28 (34, 35), suggesting that shaping 
and clasping of the hinge by the TM2/TM3 counter bearing is nec-
essary for agonist efficacy; (ii) Y1083.32, F1093.33, and F1123.36 [(35) 
and this study], proving the importance of the aromatic connector; 
and (iii) E2837.39 and M2877.43 (this study), showing the involve-
ment of residues in TM7 in the shaping of the agonist conformation 
of the chemokine and as a possible route to the rearrangement of 
W2486.48.
Gi interactions
The binding interface of Gi to CCR5 is mediated exclusively by the 
G subunit (fig. S11) and can be divided into two main regions: the 
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clearly separated parts (Fig. 5B): a proximal side formed by the end 
of the N helix (N1) and nearby  strands (23) in G and 
ICL2 in the receptor and a distal side formed by  strands (46) in 
G and ICL3 in the receptor. In addition, the rim also includes in-
teractions between 5 in Gi and ICL2/3 of the receptor. The core of 
the CCR5•Gi complex interface is formed exclusively by interac-
tions of 5 in Gi (Fig. 5A). Here, the Gi 5 helix interacts with the 
cytoplasmic sides of TM2, TM3, and TM5 in one side of the core 
binding pocket, while the C-terminal hook of 5 (residues 352 to 
354) leans toward TM6 and ICL4.
These interfaces are common to all GPCR/G protein complexes, 
as they arise from the common overall relative orientation of the 
bound components. However, analysis of the currently available 
complexes reveals that the precise location and nature of the indi-
vidual interface contacts vary to a certain degree (fig. S13). At the 
proximal rim of the interface, contacts are mostly hydrophobic and 
consistent with other Gi complexes. At the distal rim, we observe 
several ionic interactions absent in other structures. However, the 
most noticeable differences lie in the core region of the binding in-
terface, where we observe different contacts between the hook of 5 
(the last three C-terminal residues of Gi) and ICL4 of CCR5. This is 
due to a distinct conformation of ICL4 of CCR5 in which G3018.47 
and E3028.48 slightly relocate compared to, e.g., the Gi complexes of 
the neurotensin type 1 (NT1R) or -opioid (OPR) receptors, re-
sulting in a different set of interactions between E3028.48 and the 
hook of 5 (Fig. 5C). A 3D variability analysis of the cryo-EM 
density reveals structural heterogeneity around ICL4 that allows to 
model a main conformation as shown in Fig. 5C and a second mi-
nor conformation that is similar to the NTR1 and OPR complexes 
(fig. S14, A to C). The MD simulations indicate that ICL4 reverts to 
a preferred conformation in the absence of Gi (fig. S14D). An ana-
lysis of further solved GPCR•Gi structures also highlights the struc-
tural plasticity of ICL4 (fig. S15).
Structure-activity relationship of CCR5 chemokine ligands
The comparison between our structure and the inactive [5P7]
CCL5•CCR5 complex (13) allows us to precisely pinpoint the acti-
vation mechanism of CCR5 by a chemokine agonist (Fig. 6A). The 
overall binding poses of the [5P7]CCL5 antagonist (13) and the 
[6P4]CCL5 agonist are similar, with the globular core of the chemo-
kine held by the receptor N terminus and ECL2 and the chemokine 
N terminus reaching deep into the receptor TM bundle. However, 
despite having the same 10-residue length, the N termini of the two 
CCL5 derivatives differ in their amino acid sequences. This results 
in different chemokine/receptor interactions in this region: small, 
hydrophilic, or negatively charged residues in sequence positions 
4 and 5 of [6P4]CCL5 lead to a straight conformation of the proximal 
N terminus that pushes residue P3 against the bottom of CRS2. 
Thus, P3 exerts a force that is bolstered on the counter bearing hydro-











































































Fig. 4. Transmission of the chemokine agonist signal to the receptor activation switches. Top left: Residue groups connecting the N-terminal region of [6P4]CCL5 
(magenta) to key CCR5 activation switches. Relevant residues are shown as sticks. For clarity, only part of the receptor structure is shown. (A) Counter bearing in TM2/3 
and transmission through TM7. (B) Transmission through the aromatic connector. (C) Activation of the NPxxY motif and Y2145.58 in TM5. (D) Activation of the PIF motif. 
(E) Activation of the DRY motif. (F) Point mutations shown to affect CCR5 activation but not chemokine affinity [orange, mutations from literature (see main text); red, 
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and residue M2877.43. This triggers the canonical GPCR activation 
switches resulting in the relocation of TM5/6/7 and the stabilization 
of the receptor active conformation. In contrast, the large hydro-
phobic residues at positions 4 and 5 in [5P7]CCL5 force the proximal 
N-terminal hinge into a turn structure making P3 recede (Figs. 6A 
and 3B) and thereby leaving the receptor in the inactive state. The 
highly conserved (~70% in nonolfactory human class A GPCRs) 
residue W2486.48 lies at the center of these activating conformation-
al changes, connecting the rearrangements at H2897.45 and Y2446.44 
and, thus, the large-scale relocation of TM7 and TM6.
On the basis of their N-terminal sequence, we expect that other 
identified CCR5 agonist or antagonist chemokines feature respective 
similar deeper (6P4[CCL5]-active-like) or less deep (5P7[CCL5]- 
inactive-like) positions of their N-terminal turns within CRS2. Us-
ing our structure as a template, we modeled the wild-type agonist 
CCL5 bound to CCR5 (fig. S16 and movie S3). CCL5, as the [6P4]
CCL5 agonist, features an aspartate in its N terminus (D6) able to 
interact with K261.28. The MD simulations reveal a similar deep 
binding pose of the CCL5 N terminus with a straight-hinge confor-
mation of residues 5 to 8 where Y3 could be playing the role of P3 in 
[6P4]CCL5 to engage the aromatic connector and M2877.43 (Fig. 6A). 
As expected, a previous model of the active CCL5•CCR5 complex 
based on the inactive [5P7]CCL5•CCR5 structure (13) does not 
show this straight-hinge conformation but rather the inactive 
helical turn. The CCR5 chemokine agonist ligands CCL3 and CCL4 
are closely related to CCL5 having similar N-terminal sequence 
lengths and compositions (Fig. 3C). We therefore expect that these 
chemokines also adopt the straight-hinge conformation and use the 
same activation mechanism as [6P4]CCL5 or CCL5 with the aspar-
tates at position 5 and the bulky residues at position 2 carrying out 
analogous functions.
DISCUSSION
The activation mechanism in CCL5/CCR5, in which the N termi-
nus of the chemokine reaches deep into the TM bundle, differs sub-
stantially from that of CCL20/CCR6, where a much shorter CCL20 
adopts a shallower binding pose and engages a noncanonical activation 
mechanism (Figs. 3B and 6B) (17). Thus, CC chemokine receptors 
can apparently be activated through two very different mechanisms 
by “long” and “short” chemokines. But what are the molecular fea-
tures in the receptor that determine the type of activation? A phylo-
genetic analysis of CC chemokine receptors (fig. S17) puts CCR5 
and CCR6 into distinct subgroups. A more detailed sequence com-
parison of key residues in the activation mechanism shows that CC 
chemokine receptors can be divided into two main groups accord-
ing to the nature of the residue at position 6.48 (W versus Q) and, to 

















































































































Proximal Rim Interactions in the complex interface
A
Distal
Fig. 5. Binding interfaces between CCR5 and Gi. (A) Binding interfaces at the rim (left) and core (right) of the complex. Each interface is colored on the surface of the 
G protein and interacting residues in the receptor are shown as spheres (C) and sticks (side chains). (B) Residue-residue interactions at the rim of the binding interface. 
(C) Left: Structure of the 5 hook and ICL4 in the [6P4]CCL5•CCR5 complex. Key residues are shown as sticks. Right: Comparison between the 5 hook and ICL4 in the 
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receptors featuring the conserved W6.48 (CCR1, CCR2, CCR3, CCR4, 
CCR5, and CCR8) tend to be more promiscuous and preferentially 
recognize chemokines with longer N termini (9 to 14 residues) 
(Fig. 6C). On the other hand, CC chemokine receptors featuring Q6.48 
(CCR6, CCR9, CCR7, and CCR10) bind to only a few (1 to 2) chemo-
kines with short N termini (4 to 9 residues). Although position 6.48 
allows for a certain degree of variability in human class A GPCRs 
(70% W, 15% F, 5% Y, and 10% other), a Q at this position is exclusive 
of this subgroup of chemokine human receptors, supporting the 
uniqueness of this “shallow” activation mechanism.
It is interesting to observe that many chemokines undergo post-
translational proteolytic processing leading to different N-terminal 
lengths, which may constitute a layer of regulation (36, 37). Thus, a 
CCL5 variant lacking the first two N-terminal residues (CCL53–68) 
behaves as a natural chemotaxis inhibitor, and a 10-fold higher con-
centration compared to wild-type CCL5 is required to induce a sig-
nificant calcium response (37). Similarly, CCL54–68 has an about 
10-fold lower affinity for CCR5 compared to CCL53–68 or wild-type 
CCL5 and is less potent in stimulating lymphocyte chemotaxis or 
inhibiting HIV infection (36). These findings are in complete agree-
ment with the lack of contacts at the bottom of the CCR5 CRS2 
region expected for such CCL5 truncations.
The structure of CCR5  in an active conformation allows us to 
elucidate a novel activation pathway of CC chemokine receptors by 
a chemokine agonist. In CCR5 and related receptors (CCR1, CCR2, 
CCR3, and CCR4), the respective cognate chemokines have long N 
termini and bind deep into the orthosteric pocket (CRS2), thereby 
triggering the rearrangement of an aromatic connector in TM3 and 
TM6 and of the TM7 backbone. The activating force exerted by the 
deep binding [6P4]CCL5 N terminus appears to be stabilized by a 
cluster of hydrophobic CCR5 residues in TM2 and TM3 that line 
the extended N-terminal hinge of this agonist chemokine. Under-
standing this force balance may help in the design of small-molecule 
agonists, which could activate the connector region at the bottom of 
CRS2 by pushing against this counter bearing.
W6.48 lies at the center of these conformational changes connecting 
the receptor activation pathways through TM7 and TM6. In con-
trast, a subgroup of CC chemokine receptors (CCR6, CCR7, CCR9, 
and CCR10) harbors a Q residue at this position, a unique feature in 
human class A GPCRs. The cognate chemokines of these recep-
tors have shorter N termini featuring a shallow binding mode and 
a specialized mode of activation. We expect that our findings will 
help to rationalize the relationship between sequence, structure, 
and activity of chemokines and their receptors and aid drug 
discovery.
METHODS
Protein expression and purification
The wild-type human CCR5 gene containing a C-terminal 3C 
cleavage site followed by a FLAG-tag was cloned into the pFastBac1 
vector and expressed in Spodoptera frugiperda Sf9 insect cells using 
the baculoviral infection system. CCR5 expression and membrane 
preparation were performed as described (15). Membranes from 
a 1-liter culture of Sf9 cells were resuspended in 10 ml of lysis buffer 
containing iodoacetamide (2 mg/ml), and EDTA-free complete 
protease inhibitor cocktail tablets, and incubated at 4°C for 1 hour. 
Then, membranes were solubilized by supplementing 0.5% lauryl 
maltose neopentyl glycol (LMNG) at 4°C for 3 hours. The soluble 
fraction was isolated by centrifugation at 140,000g and incubated 
with 1 ml of M2 anti-FLAG affinity resin overnight at 4°C. The latter 
column was washed with 10 column volumes (CV) of washing 
buffer 1 [25 mM Hepes, 400 mM NaCl, 10% glycerol, and 0.1% LMNG 
(w/v), pH 7.5], followed by 10 CV of washing buffer 2 (25 mM Hepes, 
400 mM NaCl, 2 mM adenosine 5′-triphosphate, 5 mM MgCl2, 10% 
glycerol, and 0.1% LMNG, pH 7.5) and subsequently washed with 
another 6 CV of washing buffer 1. The receptor was eluted with 
3 CV of elution buffer consisting of 25 mM Hepes, 400 mM NaCl, 
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Fig. 6. Activation mechanism of CC chemokine receptors. (A) CCR5 bound to 
the antagonist [5P7]CCL5 (left, orange), the super-agonist [6P4]CCL5 (center, ma-
genta), and the natural agonist CCL5 (right, purple). Key residues in the activation 
mechanism of CCR5 are shown. (B) Proposed activation mechanism for CCR6 by 
CCL20 (yellow, right) by comparing with the structure of CCR9 (left). (C) Pairing 
between CC chemokine receptors and CCL chemokines (59). At the right, the se-
quence composition of key positions is shown, together with the phylogenetic re-
lationship between the receptors. The lengths of the CCL chemokine N termini 
according to UniProt (60) are shown at the bottom. The available active CCR/CCL 
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A DNA construct of [5P14]CCL5 cloned into a pET32a vector was 
a gift of P. LiWang. The DNA sequence of [6P4]CCL5 was obtained 
by mutating this [5P14]CCL5 construct using standard QuickChange 
polymerase chain reaction. [6P4]CCL5 with enterokinase-cleavable 
N-terminal thioredoxin fusion and hexa-histidine tags was ex-
pressed in the Escherichia coli BL21 (DE3) strain cultured in Lysogeny 
broth media. Protein production was induced with 1 mM isopropyl 
-d-thiogalactopyranoside when the optical density at 600 nm reached 
0.7 to 0.8. After induction, cells were grown for 20 hours at 22°C 
and then harvested by centrifugation. Ten grams of the cell pellet 
was resuspended in 50 ml of resuspension buffer (50 mM tris, 6 M 
guanidinium HCl, and 200 mM NaCl, pH 8.0) and lysed using a 
French press. The supernatant was isolated by centrifugation at 
27,000g for 1 hour and applied to a 5-ml HisTrap column. The col-
umn was washed with 10 CV of resuspension buffer and eluted with 
3 CV of 60 mM NaOAc, 200 mM NaCl, and 6 M guanidinium HCl. 
-Mercaptoethanol (20 mM) was added to the elution fraction and 
incubated for 1 hour. The denatured protein was added dropwise 
into 250 ml of folding buffer (550 mM l-arginine hydrochloride, 20 
mM tris, 200 mM NaCl, 1 mM EDTA, 1 mM reduced glutathione, 
and 0.1 oxidized glutathione, pH 8.0) and incubated overnight at 4°C. 
The solution was concentrated [molecular weight cutoff (MWCO), 
10 kDa] and dialyzed in 20 mM tris, 200 mM NaCl, and 2 mM 
CaCl2 (pH 8.0). To cleave the fusion tags, enterokinase (New England 
Biolabs) was added, and the solution was incubated for 24 hours at 
room temperature. The protein was separated from the fusion tag 
using an acetonitrile gradient on a C4 reversed-phase chromatogra-
phy column (Vydac, Hesperia, CA) and then lyophilized. The lyo-
philizate was resuspended in 25 mM phosphate buffer (pH 4). The 
N-terminal amino acid of [6P4]CCL5 glutamine (Q0) was cyclized 
at 37°C for 48 hours.
The human Gi subunit (Gi1) with an N-terminal tobacco etch 
virus (TEV) protease– cleavable deca-histidine tag was expressed in 
the E. coli BL21 (DE3) strain and purified as described (22).
The transducin heterotrimer was isolated from the rod outer 
segment of bovine retina (W L Lawson Company) and G11 was 
separated from Gt with Blue Sepharose 6 Fast Flow (GE Healthcare) 
as described (22). The Gi111 heterotrimer (Gi) was prepared by 
mixing equimolar amounts of Gi1 and G11 and incubated at 4°C 
for 1  hour shortly before use for CCR5-Gi complex formation. 
Fab16 was produced by papain digestion of immunoglobulin G16 
as described (22).
Formation of the [6P4]CCL5•CCR5•Gi•Fab16 complex
Pooled fractions of CCR5 eluted from the anti-FLAG resin and a 
molar excess of Gi heterotrimer were mixed together and incubated 
for 30 min. Then, an equimolar amount of [6P4]CCL5, together 
with apyrase (25 mU/ml), was added and incubated for another 
2  hours. The complex was mixed with molar excess (1:1.4) of 
Fab16 and further incubated for at least 1 hour. The mixture of 
[6P4]CCL5•CCR5•Gi and Fab16 was concentrated using an 
Amicon Ultra concentrator (MWCO, 100 kDa) and loaded onto 
a Superdex 200 Increase 10/300 GL column for size exclusion chroma-
tography (SEC) with buffer containing 25 mM Hepes, 150 mM 
NaCl, and 0.01% LMNG (pH 7.5). The protein quality of each 
fraction was evaluated by SDS–polyacrylamide gel electrophore-
sis (fig. S1, A and B). Fractions showing good purity and complex 
integrity were pooled together and concentrated for EM grid 
preparation.
Cryo-EM sample preparation and image acquisition
For cryo-EM, 3.5 l sample (2.5 mg/ml) was directly applied to 
glow-discharged 200-mesh carbon grids (Quantifoil Cu R1.2/1.3, 
200 mesh). Grids were immediately plunge-frozen in liquid ethane 
using an FEI Vitrobot Mark IV (Thermo Fisher Scientific) with a 
blotting time of 3 s. The grids were screened for ice thickness and 
particle distribution using a Glacios Cryo-TEM operated at 200 kV. 
Images were acquired from the selected grid using a Glacios Cryo-
TEM (Thermo Fisher Scientific) operated at 200 kV equipped with 
a Gatan K3 Summit direct electron detector (Gatan Inc.). Automated 
data collection was carried out using SerialEM with a set of custom-
ized scripts enabling automated low-dose image acquisition (38, 39) 
and online prescreened during data collection using FOCUS (40). 
Movie stacks of 40 frames were obtained with a defocus range 
of −1.0 to −2.0 m at a magnification of ×45,000 (nominally 
×36,000) and the K3 detector operated in super-resolution mode 
(super-resolution pixel size, 0.556 Å). Each movie had a total accu-
mulated dose exposure of ~49 e/Å2. A total of 2586 image stacks 
were collected for the [6P4]CCL5•CCR5•Gi•Fab16 complex.
Cryo-EM data processing
Contaminated micrographs were removed manually. Patch motion cor-
rection and patch contrast transfer function (CTF) parameter estima-
tion were performed using algorithms implemented in cryoSPARC 
v2.15.0 (41). After sorting, micrographs with estimated resolution 
worse than 6.0 Å were discarded. The remaining motion-corrected 
images summed with dose weighting were used for all further image 
processing in cryoSPARC. Approximately 2.6 million particles were 
auto-picked and subjected to several rounds of reference-free 2D 
classification to remove false-positive particles. A total of 345,458 par-
ticles from 3D classes that demonstrated clear structural features were 
combined and subjected to 3D refinement, which led to a reconstruc-
tion at 3.6-Å resolution. Nonuniform refinement (42) with subse-
quent local refinements was performed in cryoSPARC v3.1.0 and 
improved the overall resolution to 3.15 Å [Fourier shell correlation 
(FSC) = 0.143].
The final set of homogeneous [6P4]CCL5•CCR5•Gi•Fab16 complex 
particles was subjected to 3D variability analysis implemented in 
CryoSPARC (43) using three variability components and a low-pass 
filter resolution of 4 Å after applying a soft mask to exclude solvent 
and micelle.
Reported resolutions calculated with a soft shape mask are based 
on the gold-standard FSC using the 0.143 criterion. The local reso-
lution was determined using ResMap (44).
Model building and refinement
The crystal structures of the Gi heterotrimer [Protein Data Bank 
(PDB) ID: 5KDO], Fab16 (PDB ID: 6QNK), and the [5P7]CCL5•CCR5 
complex (PDB ID: 5UIW) were used as initial templates for model 
building. The models were docked into the 3D map as rigid bodies 
in Chimera (45). The [6P4]CCL5 N terminus (up to the residue 9) 
was built ab initio. As compared to residues 1 to 9, a lower defini-
tion of the density was observed in the region of the N-terminal 
pyroglutamate (PCA0). The remaining part of [6P4]CCL5 was taken 
from the 5UIW structure. Several rounds of manual building were 
performed in Coot (46). The model was finalized by refinement in 
Phenix 1.18.2. (47) against the 3.15-Å cryo-EM map. Structural fig-
ures were prepared in Chimera and PyMOL (https://pymol.org/2/). 
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Amino acid sequence analysis
The analysis of N-terminal sequence similarity of the natural amino 
acid CCL5 variants (table S2) was carried using WebLogo (48).
Characterization of resistance to GTPS
To assess the stability of the purified [6P4]CCL5•CCR5•Gi com-
plexes with or without Fab16, they were incubated with 100 M 
guanosine 5′-O-(3′-thiotriphosphate) (GTPS) in 25 mM Hepes, 
150 mM NaCl, and 0.01% LMNG (pH 7.5) for 1 hour at 4°C and 
analyzed by SEC with a Superdex 200 Increase 10/300 GL column 
monitoring the protein intrinsic tryptophan fluorescence (ex = 280 nm; 
em = 350 nm). As standards, SEC analyses were also carried out on 
purified Fab16, G, Gi, and mixtures thereof using identical buf-
fer conditions. The respective chromatograms are shown in fig. S1C.
Cellular Ca2+ flux assays for receptor activation
Human CCL5 and reference standard [6P4]CCL5 were prepared by 
chemical synthesis as previously described (10, 11). [6P4]CCL5 
variants (D5A and D5K), as well as a sample of unmodified [6P4]
CCL5, were prepared using a previously described multiplex chem-
ical synthesis approach (49).
For experiments involving CCR5 mutants, HEK cells were tran-
siently transfected with expression vectors obtained by site-directed 
mutagenesis (Q5 Site-Directed Mutagenesis kit, New England Bio-
labs) of the parent FUGW-CCR5 vector, which was generated by 
Gibson Assembly (New England Biolabs) as previously described 
(50). HEK cells (1.25 × 106) were seeded overnight in 10-cm dishes 
and transfected with CCR5 expression vectors (jetPRIME, Polyplus 
Transfection) according to the manufacturer’s instructions. Cells 
were used in Ca2+ flux experiments 24 hours later. For experiments 
involving [6P4]CCL5 variants, HEK (10) and CHO (49) cell clones 
stably expressing CCR5 (HEK-CCR5 and CHO-CCR5, respectively) 
were used.
Ca2+ flux measurements were performed using a Functional Drug 
Screening System (FDSS) microcell device (HAMAMATSU). On the 
day of the experiment, cells were detached in phosphate-buffered 
saline (PBS) supplemented with 0.48 mM EDTA and added (20,000 cells 
per well) to wells of black-walled clear-bottom 384-well plates. Cells 
were then loaded with a calcium-sensitive fluorescent dye (Screen 
Quest Fluo-8 No Wash Calcium Assay Kit, AAT Bioquest) according 
to the manufacturer’s instructions. Fluorescence signals (excitation, 
490 nm; emission, 525 nm) were recorded before and after addition 
of agonist (dissolved in PBS supplemented with 1% bovine serum 
albumin and 25 mM Hepes) at defined concentrations. Agonist re-
sponses were defined as the maximum Ca2+ flux fluorescence signal 
divided by that of a control well with cells treated with buffer only. 
Dose- response curves were fitted (GraphPad Prism) to the agonist 
responses R at each concentration using a three-parameter agonist 
versus response model,  R =  R 0 +   [agonist
 ] × ( R max −  R 0 )  _____________ EC 50 + [agonist] , where R0 presents the baseline and Rmax − R0 = Emax.
Modeling and MD simulations
CCR5 N-terminal residues 1 to 19 were built using as template res-
idues 1 to 14 of the NMR solution structure of a doubly sulfated (at 
Y10 and Y14) N-terminal segment of CCR5 bound to CCL5 (PDB 
ID: 6FGP). The chemokine in the latter structure was then used as a 
guide for the structural alignment to our cryo-EM structure. Re-
maining residues 15 to 19 of CCR5 were then connected to the 
rest of the cryo-EM model using Modeller v9.16 (51). All models 
derived from Modeller were then subjected to 300 iterations of vari-
able target function method optimization and MD and simulated 
annealing optimization (within Modeller), scored using the discrete 
optimized protein energy potential, and the best-scoring model was 
selected (Fig. 1D, right).
This model of CCR5 (residues 1 to 320) bound to [6P4]CCL5 
was used for MD simulations of the nonsulfated and sulfated (Y10 and 
Y14) forms. Coordinates were first preprocessed using VMD1.9.3 (52). 
The receptor-ligand complex (i.e., CCR5-[6P4]CCL5 or CCR5-CCL5) 
was then embedded into a 90 Å × 90 Å lipid bilayer composed of 
80% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 20% 
cholesterol. The system was solvated with explicit water mole-
cules, neutralized, and its ionic strength was adjusted using the 
CHARMM-GUI builder (53). Disulfide bridges were explicitly de-
fined between C50-C11 and C34-C10 in CCL5 or [6P4]CCR5 and 
C1013.25-C178 and C20-C2697.25 in CCR5. Except for CCR5 resi-
dues D762.50, E2837.39, and E3028.48, which were protonated, all 
titratable residues of CCR5 and CCL5 were left in their dominant 
protonation state at pH 7.0. Before production runs, the geometry 
of the system was optimized by energy minimization and further 
relaxed by a sequence of equilibration steps where harmonic posi-
tional restraints were applied to all C atoms of the protein and 
gradually released throughout the equilibration. In the last equili-
bration step (i.e., before completely releasing all protein restraints), 
water, ion, and lipids were allowed to diffuse without restraints 
during 50 ns to allow for adequate equilibration of the lipid mixture. 
After equilibration was completed, five independent trajectories of 
each system were spawned from the last snapshot of the equilibrated 
trajectory using a random seed. Production simulations for each 
replica were run in the isothermal-isobaric (NPT) ensemble at 1013 bar 
and 310 K for 500 ns each. All simulations were run using Gromacs 
v2020 (54) with the CHARMM36m force field (55). Gromacs v2020 
and VMD1.9.31 were used to postprocess and analyze all trajectories. 
MD simulation figures were rendered using VMD1.9.3 and the R 
ggplot2 library (56). Circular plots of residue contacts were generated 
using the mdciao library (57).
The equilibrated model [6P4]CCL5 bound to CCR5 was used to 
model the binding pose of the wild-type CCL5. The sequence of 
CCL5 was threaded on [6P4]CCL5 (6P4: QGPPGDIVLACC/CCL5: 
SPYSSDTTP-CC) and steric clashes were relieved using the molecular 
graphics software PyMOL. Using this structure as a template, resi-
dues 1 to 9 of CCL5 and all residues within 8 Å around Y3 of CCL5 
were remodeled with Modeller v9.16 using the protocol described 
above. The stability of the resulting binding pose was assessed by 
MD simulations using the protocol described above.
A list of simulations performed in this work is given in table S4. 
MD simulations were performed at the Paul Scherrer Institute 
computing cluster and at the Swiss National Supercomputing 
Centre (CSCS).
Electrostatic potentials were calculated using the Adaptive Poisson- 
Boltzmann Solver (APBS) method (58) as implemented in PyMOL 
using a concentration of 0.150 M for the +1 and 1 ion species. The 
biomolecular surface is colored from red (5 kT/e) to blue (+5 kT/e) 
according to the potential on the soluble accessible surface.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/25/eabg8685/DC1
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